TABLE 1.

Induction of luciferase expression with proteasome-modulating agents^a

Cell line	Mean ± SEM induction (fold) of luciferase activity in the presence of:
	Aclarubicin		Doxorubicin		LLnL
	rAAV-2	rAAV-5	rAAV-2	rAAV-5	rAAV-2	rAAV-5
IB3	150.0 ± 13.9	324.1 ± 3.0	118.2 ± 0.6	324.13 ± 3.6	273 ± 16.2	149 ± 12.6
A549	187 ± 10.7	265.4 ± 8.8	426.4 ± 3.3	339.4 ± 10.4	29.5 ± 6.1	23.12 ± 1.2
Polarized airway epithelia	54.1 ± 4.5	29.5 ± 3.2	147.9 ± 29.7	84.5 ± 12.7	3.3 ± 0.8	3.8 ± 0.5

^aData are derived from four (IB3 and A549) and three (polarized cell) independent experiments. Luciferase assays were performed at 24 h postinfection with IB3 and A549 cells and at 17 days postinfection with human polarized airway cells. Induction was calculated with the following formula for each experimental point: relative luciferase activity with proteasome-modulating agent/relative luciferase activity without proteasome-modulating agent. The optimal doses of each compound are as follows: aclarubicin, 0.25 μM for all cell lines; doxorubicin, 2 μM for IB3 cells and 5 μM for A549 cells and polarized airway epithelia; LLnL, 40 μM for IB3 cells and polarized airway epithelia and 400 μM for A549 cells.